US20020092583A1 - Medical devices, particularly stents, and methods for their manufacture - Google Patents
Medical devices, particularly stents, and methods for their manufacture Download PDFInfo
- Publication number
- US20020092583A1 US20020092583A1 US09/760,595 US76059501A US2002092583A1 US 20020092583 A1 US20020092583 A1 US 20020092583A1 US 76059501 A US76059501 A US 76059501A US 2002092583 A1 US2002092583 A1 US 2002092583A1
- Authority
- US
- United States
- Prior art keywords
- alloy
- treatment
- component
- stent
- surface region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C8/00—Solid state diffusion of only non-metal elements into metallic material surfaces; Chemical surface treatment of metallic material by reaction of the surface with a reactive gas, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals
- C23C8/06—Solid state diffusion of only non-metal elements into metallic material surfaces; Chemical surface treatment of metallic material by reaction of the surface with a reactive gas, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals using gases
- C23C8/08—Solid state diffusion of only non-metal elements into metallic material surfaces; Chemical surface treatment of metallic material by reaction of the surface with a reactive gas, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals using gases only one element being applied
- C23C8/10—Oxidising
- C23C8/16—Oxidising using oxygen-containing compounds, e.g. water, carbon dioxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22F—CHANGING THE PHYSICAL STRUCTURE OF NON-FERROUS METALS AND NON-FERROUS ALLOYS
- C22F1/00—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
- C22F1/006—Resulting in heat recoverable alloys with a memory effect
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23F—NON-MECHANICAL REMOVAL OF METALLIC MATERIAL FROM SURFACE; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL; MULTI-STEP PROCESSES FOR SURFACE TREATMENT OF METALLIC MATERIAL INVOLVING AT LEAST ONE PROCESS PROVIDED FOR IN CLASS C23 AND AT LEAST ONE PROCESS COVERED BY SUBCLASS C21D OR C22F OR CLASS C25
- C23F1/00—Etching metallic material by chemical means
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D11/00—Electrolytic coating by surface reaction, i.e. forming conversion layers
- C25D11/02—Anodisation
- C25D11/26—Anodisation of refractory metals or alloys based thereon
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D11/00—Electrolytic coating by surface reaction, i.e. forming conversion layers
- C25D11/02—Anodisation
- C25D11/34—Anodisation of metals or alloys not provided for in groups C25D11/04 - C25D11/32
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91533—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
Definitions
- This invention relates to medical devices and to a method of making medical devices. More particularly, this invention relates to stents and a method for making stents. Most particularly, this invention relates to self-expanding Ni—Ti stents and methods for making such stents.
- nickel containing alloys in medical devices is well established.
- such alloys are nickel-titanium-based alloys, which are used because of their ability to exhibit shape memory properties associated with transformations between the martensitic and austenitic phases. These properties include thermally induced changes in configuration in which an article is first deformed from a heat-stable configuration to a heat-unstable configuration while the alloy is in its martensitic phase. Subsequent exposure to increased temperature results in a change in configuration from the heat-unstable configuration towards the original heat-stable configuration as the alloy reverts from its martensite phase to its austenite phase.
- Shape memory alloys can also exhibit enhanced elastic properties compared with materials that do not exhibit martensite-austenite transformations.
- the nature of the superelastic transformations of shape memory alloys is discussed in “Engineering Aspects of Shape Memory Alloys”, T. W. Duerig et al, 370, Butterworth-Heinemann (1990). Subject matter disclosed in that document is incorporated herein by reference.
- a principal transformation of shape memory alloys involves an initial increase in strain, approximately linearly with stress. This behavior is reversible, and corresponds to conventional elastic deformation. Subsequent increases in strain are accompanied by little or no increase in stress, over a limited range of strain to the end of the “loading plateau”. The inflection point on a stress v.
- strain graph defines the loading plateau stress. Subsequent increases in strain are accompanied by increases in stress. Upon unloading, there is a decline in stress with reducing strain to the start of the “unloading plateau” evidenced by the existence of an inflection point along which stress changes little with reducing strain. At the end of the unloading plateau, stress reduces, with reducing strain. The inflection point on the stress v. graph also defines the unloading plateau stress. Any residual strain after unloading to zero stress is the “permanent set” of the sample.
- Characteristics of this deformation are established, and are defined in, for example, “Engineering Aspects of Shape Memory Alloys”, supra at 376.
- Ni—Ti alloys are considered biocompatible. However, it can be desirable for some applications to use an alloy in which the nickel content is outside the range considered acceptable for in vivo use, in particular to achieve a desired physical behavior in the alloy.
- One recently employed method to obtain a low-Ni, biocompatible surface is to use electrochemical methods.
- One particular concept described by this invention is to disclose alternative means to simultaneously decrease Ni content and increase biocompatibility in Ni—Ti alloys.
- the present invention provides medical devices whose biocompatibility in relation to nickel content is improved.
- the invention provides a medical device which includes a component formed from an alloy which contains at least about 40% Ni, the alloy in a 10 nm deep surface region of the component containing not more than about 10% Ni.
- the reduction of the nickel content of the alloy in a surface region of the Ni-alloy component can make the device of the invention more easily accepted for in vivo use by reducing the risk of toxic or carcinogenic side effects and by preventing its physical degradation.
- the Ni content in the said surface region is reduced to not more than about 5%, more preferably not more than about 3%, especially not more than about 1.5%.
- the alloy from which the component is formed is a Ni—Ti based alloy, for example a Ni—Ti binary alloy.
- the alloy can contain more than two elements, for example a ternary alloy or a quaternary alloy.
- elements that can be included in a Ni—Ti based alloy include Fe, Cu, Co, Zr, Hf, B and Nb.
- the alloy contains at least about 48% Ni, more, preferably at least about 50%.
- An example of a particularly preferred alloy is a binary alloy containing about 50.8% Ni.
- Ni content in the surface region can be determined by known spectroscopic techniques such as Auger spectroscopy, X-ray Photoelectron Spectroscopy (XPS) or Secondary Ion Mass spectroscopy (SIMS). The content is measured in a 10 nm deep layer over the area in which the component has been treated.
- XPS X-ray Photoelectron Spectroscopy
- SIMS Secondary Ion Mass spectroscopy
- the invention provides a method of making a medical device comprising a component formed from an alloy which contains nickel, which includes the step of exposing the component in a surface region thereof to a treatment which causes the Ni content of the alloy in that region to be reduced compared with that in the remainder of the component.
- Ni content of the alloy in the said surface region can be reduced by specialized oxidizing treatments.
- treatments to which the component can be exposed include exposure to a chemical solution, exposure to superheated steam, and an electrochemical treatment.
- Such treatments can cause alloy elements other than nickel to be oxidized, to form an oxide layer on the component.
- these treatments will effectively remove surface Ni atoms, thereby promoting the oxidation of Ti.
- treatment of a Ni—Ti alloy can result in the formation of a surface layer of TiO 2 .
- a treatment which involves exposure to superheated steam will preferably involve exposure for at least about 1.5 hours, preferably at least about 3 hours, more preferably at least about 5 hours.
- the steam is heated to at least about 120 ⁇ C., more preferably at least about 150 ⁇ C.
- the component is preferably included in an electrochemical system as the anode.
- the component is preferably immersed in acidic or basic solutions to modify the surface chemistry.
- the Ni alloy component of the device is preferably treated so that it exhibits shape memory properties making it suitable for the particular application for the device.
- the component can be treated so that it exhibits a thermally induced change in configuration as a result of a change in phase between austenite and martensite phases due to a change in temperature.
- the component will be treated so that it exhibits enhanced elastic properties such as those referred to as “superelastic” properties.
- the medical device of the invention can be designed for any of a large number of applications.
- a particularly preferred device is a stent formed from an alloy, which has been treated so that it exhibits enhanced elastic properties.
- a stent can be inserted into a lumen while constrained in a transversely compressed configuration, and then allowed to expand so that it contacts the wall of the lumen to support it, and in some applications, also radially forced outwardly.
- the stent is left in situ in the lumen to provide this support to the lumen.
- FIG. 1 is a perspective view of a stent made according to the process described herein.
- Ni—Ti alloys containing between 50% and 60% nickel by weight, are currently of great interest to the medical industry due to their superelastic and shape memory properties. These properties provide value for the design of various medical implants, such as stents, suture and bone anchors, archwire, and orthopaedic devices. As is well understood, implants made from these alloys require highly biocompatible surface finishes. Among the requirements of high biocompatibility are low uniform corrosion rates, high resistance to localized corrosion, low toxicity, and low thrombogenicity.
- Unalloyed nickel is considered a toxic and carcinogenic substance. While NiTi alloys contain high nickel content, such a characteristic does not result in toxicity per se. In order to be toxic, nickel must be released to the environment of the device through corrosion processes. Thrombogenicity is a complicated matter, depending on the design of the device, the environment, surface chemistry and surface roughness.
- Ni-free in this case, is defined as less than 5% nickel in the top 10 nm of the material.
- the process consists of two steps: polishing and oxidizing.
- the polishing process should be a polishing step that removes the existing oxide layer and leaves a surface finish of RMS 2 or better.
- One preferred method would be to electropolish in acidic solutions at temperatures below room temperature. These colder temperature processes result in a lower material removal rate. Lower material removal rates are more conducive to polishing complex parts with small cross sectional areas. (Larger material removal rates dictate larger currents. These cannot be uniformly carried through small cross sectional areas without excessive heating.) Polishing may be improved by preceding treatments to remove oxide layers, such as mechanical polishing and/or chemical etching.
- the oxidation process can consist of a steam sterilization treatment, or better a surface treatment in a chemical solution, or even better an anodizing process. All these processes remove the Nickel from the surface and leave behind a surface film of Rutile (TiO 2 ). Immersion of the Ni—Ti component in an acidic or basic chemical solution will selectively remove the existing surface layer and promote the formation of TiO 2 . Anodizing appears to significantly reduce the corrosion current in the passive regime and increase the corrosion potential toward more noble values.
- a stent is made from a tube of a Ni—Ti binary alloy.
- a stent 10 which may be formed according to the described invention is seen in FIG. 1.
- the tube from which the stent is formed is made from a Ni—Ti binary alloy which contains 50.8% Ni by weight.
- the tube has an external diameter of about 3 mm and a wall thickness of about 0.4 mm. Any conventional tube forming techniques, such as drawing, etching, etc, may be used to form the tube.
- a pattern is cut into the tube so that it adopts a configuration similar to that described in FIG. 1, in which there are slots 12 cut out of the tube.
- Conventional etching and laser cutting techniques may be used to create slots 12 into the tube, so that it forms stent 10 .
- These slots 12 enable the radial dimension of the tube to be changed by causing the struts 14 to deform relative to one another.
- stents such as the Palmaz® stent, Palmaz-Schatz® stent, Crown® stent, and Bx Velocity® stent, all made by the parent company of the present assignee, and incorporated herein by reference, are all suitable designs of stents for the herein described process.
- Suitable cutting techniques include laser machining (for example using a YAG laser), electric discharge machining, chemical etching and machining.
- the stent is treated so that the alloy exhibits superelastic properties by a process that includes a succession of cold working and heat treatment steps (such as those found in Duerig et al., U.S. Pat. No. 5,843,244. owned by a common assignee and incorporated herein by reference.)
- the stent is cold worked by fitting it onto a succession of mandrels of increasing sizes.
- the stent is heat treated after each cold working step by exposing it to an elevated temperature (that is below the re-crystallization temperature of the alloy) while it is constrained in the configuration resulting from the cold work.
- a suitable heat treatment temperature is in the range 400° C. to 450° C.
- a succession of cold work and heat treatment steps can be used to impart an appropriate amount of cold work to the stent, which could result in a permanent deformation if carried out in a single step.
- the stent After the cold work and heat treatment steps, the stent has superelastic properties so that it can be deformed inwardly towards the configuration as cut, and will then recover elastically towards the configuration from which it was deformed inwardly.
- the stent 10 could then be electropolished at temperatures below 20° C. using methanol-sulfuric acid solutions. If necessary, the stent 10 may be “primed” for polishing, by using prior treatments to remove oxide layers, such as mechanical methods (e.g., grit blasting) and/or chemical etching.
- the Ni content in the alloy in a surface region of the stent is reduced is by an oxidizing treatment involving exposure to superheated steam at 150° C. for 12 hours.
- the stent surface resulting from this treatment contains TiO 2 . From Auger spectroscopy, the Ni content in a surface region 10 nm deep has been found to be less than 2% by weight.
- the sulfuric acid bath can be adequately substituted with other acid-based solutions, such as HNO 3 , perchloric acid, etc.
- the concept applied by this step is to place the medical device into the solution bath, apply a potential, and use the device as an anode in the process.
- electropolishing selectively removes base material, which may contain contaminants, and allows re-growth of the passive oxide on the device surface with a low Nickel content contained thereon.
- electromechanical methods described above may further be substituted with purely chemical methods. For instance, one may use one of the following solutions:
- Acidic e.g., 10% to 50% HNO 3 (preferably 20% to 40% HNO 3 ; more preferably 30% HNO 3 —water solution);
- Neutral e.g., saline-based, such as 0.2% to 5% NaCl, preferably 0.5% to 1.5% NaCl, more preferably 0.9% NaCl—water solution;
- the step may include anodizing.
- This includes exposure of the medical device to a chemical solution (acidic, neutral or basic) with an appropriately applied potential in order to grow a more stable passive oxide layer.
- a chemical solution acidic, neutral or basic
- an appropriately applied potential in order to grow a more stable passive oxide layer.
- one procedure would be to immerse the NiTi medical device in a saline-based solution, and hold the potential at about 200 mV to 1000 mV, preferably 300 mV to 700 mV, more preferably 500 mV for 0.1 to 10 hours, preferably 0.2 to 2 hours, more preferably 0.5 to 1 hour.
Abstract
A medical device which includes a component formed from an alloy which contains at least about 40% Ni by weight. The alloy in a 10 nm deep surface region of the component contains not more than about 10% Ni by weight. The Ni content in that surface region can be reduced by polishing and oxidizing treatment such as (a) exposure to superheated steam, or (b) immersion in a chemical solution, or (c) an electrochemical treatment, using the device as the anode in a solution bath with a current running therethrough.
Description
- This invention relates to medical devices and to a method of making medical devices. More particularly, this invention relates to stents and a method for making stents. Most particularly, this invention relates to self-expanding Ni—Ti stents and methods for making such stents.
- The use of nickel containing alloys in medical devices is well established. Examples of such alloys are nickel-titanium-based alloys, which are used because of their ability to exhibit shape memory properties associated with transformations between the martensitic and austenitic phases. These properties include thermally induced changes in configuration in which an article is first deformed from a heat-stable configuration to a heat-unstable configuration while the alloy is in its martensitic phase. Subsequent exposure to increased temperature results in a change in configuration from the heat-unstable configuration towards the original heat-stable configuration as the alloy reverts from its martensite phase to its austenite phase.
- Shape memory alloys can also exhibit enhanced elastic properties compared with materials that do not exhibit martensite-austenite transformations. The nature of the superelastic transformations of shape memory alloys is discussed in “Engineering Aspects of Shape Memory Alloys”, T. W. Duerig et al, 370, Butterworth-Heinemann (1990). Subject matter disclosed in that document is incorporated herein by reference. A principal transformation of shape memory alloys involves an initial increase in strain, approximately linearly with stress. This behavior is reversible, and corresponds to conventional elastic deformation. Subsequent increases in strain are accompanied by little or no increase in stress, over a limited range of strain to the end of the “loading plateau”. The inflection point on a stress v. strain graph defines the loading plateau stress. Subsequent increases in strain are accompanied by increases in stress. Upon unloading, there is a decline in stress with reducing strain to the start of the “unloading plateau” evidenced by the existence of an inflection point along which stress changes little with reducing strain. At the end of the unloading plateau, stress reduces, with reducing strain. The inflection point on the stress v. graph also defines the unloading plateau stress. Any residual strain after unloading to zero stress is the “permanent set” of the sample. Characteristics of this deformation, the loading plateau, the unloading plateau, the elastic modulus, the plateau length and the permanent set (defined with respect to a specific total deformation) are established, and are defined in, for example, “Engineering Aspects of Shape Memory Alloys”, supra at 376.
- Many Ni—Ti alloys are considered biocompatible. However, it can be desirable for some applications to use an alloy in which the nickel content is outside the range considered acceptable for in vivo use, in particular to achieve a desired physical behavior in the alloy. One recently employed method to obtain a low-Ni, biocompatible surface is to use electrochemical methods. One particular concept described by this invention is to disclose alternative means to simultaneously decrease Ni content and increase biocompatibility in Ni—Ti alloys.
- The present invention provides medical devices whose biocompatibility in relation to nickel content is improved.
- Accordingly, in one aspect, the invention provides a medical device which includes a component formed from an alloy which contains at least about 40% Ni, the alloy in a 10 nm deep surface region of the component containing not more than about 10% Ni.
- It has been found that the reduction of the nickel content of the alloy in a surface region of the Ni-alloy component can make the device of the invention more easily accepted for in vivo use by reducing the risk of toxic or carcinogenic side effects and by preventing its physical degradation. Preferably, the Ni content in the said surface region is reduced to not more than about 5%, more preferably not more than about 3%, especially not more than about 1.5%.
- Preferably, the alloy from which the component is formed is a Ni—Ti based alloy, for example a Ni—Ti binary alloy. However, the alloy can contain more than two elements, for example a ternary alloy or a quaternary alloy. Examples of elements that can be included in a Ni—Ti based alloy include Fe, Cu, Co, Zr, Hf, B and Nb.
- Preferably, the alloy contains at least about 48% Ni, more, preferably at least about 50%. An example of a particularly preferred alloy is a binary alloy containing about 50.8% Ni.
- The Ni content in the surface region can be determined by known spectroscopic techniques such as Auger spectroscopy, X-ray Photoelectron Spectroscopy (XPS) or Secondary Ion Mass spectroscopy (SIMS). The content is measured in a 10 nm deep layer over the area in which the component has been treated.
- In another aspect, the invention provides a method of making a medical device comprising a component formed from an alloy which contains nickel, which includes the step of exposing the component in a surface region thereof to a treatment which causes the Ni content of the alloy in that region to be reduced compared with that in the remainder of the component.
- The Ni content of the alloy in the said surface region can be reduced by specialized oxidizing treatments. Whereas, several investigators have tried to improve corrosion resistance by thermal oxidation heat treatments, there has been little success. Examples of treatments to which the component can be exposed include exposure to a chemical solution, exposure to superheated steam, and an electrochemical treatment. Such treatments can cause alloy elements other than nickel to be oxidized, to form an oxide layer on the component. Simultaneously, these treatments will effectively remove surface Ni atoms, thereby promoting the oxidation of Ti. For example, treatment of a Ni—Ti alloy can result in the formation of a surface layer of TiO2.
- A treatment which involves exposure to superheated steam will preferably involve exposure for at least about 1.5 hours, preferably at least about 3 hours, more preferably at least about 5 hours. Preferably, the steam is heated to at least about 120□ C., more preferably at least about 150□ C.
- In electrochemical treatments of the alloy, the component is preferably included in an electrochemical system as the anode.
- In chemical treatments of the alloy, the component is preferably immersed in acidic or basic solutions to modify the surface chemistry.
- The Ni alloy component of the device is preferably treated so that it exhibits shape memory properties making it suitable for the particular application for the device. For example, the component can be treated so that it exhibits a thermally induced change in configuration as a result of a change in phase between austenite and martensite phases due to a change in temperature. For many applications, the component will be treated so that it exhibits enhanced elastic properties such as those referred to as “superelastic” properties.
- The medical device of the invention can be designed for any of a large number of applications. A particularly preferred device is a stent formed from an alloy, which has been treated so that it exhibits enhanced elastic properties. A stent can be inserted into a lumen while constrained in a transversely compressed configuration, and then allowed to expand so that it contacts the wall of the lumen to support it, and in some applications, also radially forced outwardly. The stent is left in situ in the lumen to provide this support to the lumen. The reduction of the risk of complications due to adverse biocompatibility reactions that can be achieved by the present invention gives rise to particular advantages in a device that is used in this way.
- The invention will be better understood by reference to the drawings, in which:
- FIG. 1 is a perspective view of a stent made according to the process described herein.
- Ni—Ti alloys, containing between 50% and 60% nickel by weight, are currently of great interest to the medical industry due to their superelastic and shape memory properties. These properties provide value for the design of various medical implants, such as stents, suture and bone anchors, archwire, and orthopaedic devices. As is well understood, implants made from these alloys require highly biocompatible surface finishes. Among the requirements of high biocompatibility are low uniform corrosion rates, high resistance to localized corrosion, low toxicity, and low thrombogenicity.
- Unalloyed nickel is considered a toxic and carcinogenic substance. While NiTi alloys contain high nickel content, such a characteristic does not result in toxicity per se. In order to be toxic, nickel must be released to the environment of the device through corrosion processes. Thrombogenicity is a complicated matter, depending on the design of the device, the environment, surface chemistry and surface roughness.
- The process according to the current invention describes a process to produce a very smooth and Ni-free surface on Ni—Ti. “Ni-free” in this case, is defined as less than 5% nickel in the top 10 nm of the material. The process consists of two steps: polishing and oxidizing.
- Ideally, the polishing process should be a polishing step that removes the existing oxide layer and leaves a surface finish of RMS 2 or better. One preferred method would be to electropolish in acidic solutions at temperatures below room temperature. These colder temperature processes result in a lower material removal rate. Lower material removal rates are more conducive to polishing complex parts with small cross sectional areas. (Larger material removal rates dictate larger currents. These cannot be uniformly carried through small cross sectional areas without excessive heating.) Polishing may be improved by preceding treatments to remove oxide layers, such as mechanical polishing and/or chemical etching.
- The oxidation process can consist of a steam sterilization treatment, or better a surface treatment in a chemical solution, or even better an anodizing process. All these processes remove the Nickel from the surface and leave behind a surface film of Rutile (TiO2). Immersion of the Ni—Ti component in an acidic or basic chemical solution will selectively remove the existing surface layer and promote the formation of TiO2. Anodizing appears to significantly reduce the corrosion current in the passive regime and increase the corrosion potential toward more noble values.
- The present invention can perhaps best be understood by reference to an example of a stent made according to the disclosed processes.
- The invention is described by way of a stent is made from a tube of a Ni—Ti binary alloy. (A stent10 which may be formed according to the described invention is seen in FIG. 1.)
- The tube from which the stent is formed is made from a Ni—Ti binary alloy which contains 50.8% Ni by weight. The tube has an external diameter of about 3 mm and a wall thickness of about 0.4 mm. Any conventional tube forming techniques, such as drawing, etching, etc, may be used to form the tube.
- A pattern is cut into the tube so that it adopts a configuration similar to that described in FIG. 1, in which there are
slots 12 cut out of the tube. Conventional etching and laser cutting techniques may be used to createslots 12 into the tube, so that it forms stent 10. Theseslots 12 enable the radial dimension of the tube to be changed by causing the struts 14 to deform relative to one another. (It is also well understood that a segment of wire may be formed intoslots 12, so that the effect of the expansion is identical to the slots formed by other processes.) Other suitable configurations of stents will be apparent; for example, stents such as the Palmaz® stent, Palmaz-Schatz® stent, Crown® stent, and Bx Velocity® stent, all made by the parent company of the present assignee, and incorporated herein by reference, are all suitable designs of stents for the herein described process. Suitable cutting techniques include laser machining (for example using a YAG laser), electric discharge machining, chemical etching and machining. - The stent is treated so that the alloy exhibits superelastic properties by a process that includes a succession of cold working and heat treatment steps (such as those found in Duerig et al., U.S. Pat. No. 5,843,244. owned by a common assignee and incorporated herein by reference.) The stent is cold worked by fitting it onto a succession of mandrels of increasing sizes. The stent is heat treated after each cold working step by exposing it to an elevated temperature (that is below the re-crystallization temperature of the alloy) while it is constrained in the configuration resulting from the cold work. A suitable heat treatment temperature is in the range 400° C. to 450° C. A succession of cold work and heat treatment steps can be used to impart an appropriate amount of cold work to the stent, which could result in a permanent deformation if carried out in a single step.
- After the cold work and heat treatment steps, the stent has superelastic properties so that it can be deformed inwardly towards the configuration as cut, and will then recover elastically towards the configuration from which it was deformed inwardly.
- The stent10 could then be electropolished at temperatures below 20° C. using methanol-sulfuric acid solutions. If necessary, the stent 10 may be “primed” for polishing, by using prior treatments to remove oxide layers, such as mechanical methods (e.g., grit blasting) and/or chemical etching.
- The Ni content in the alloy in a surface region of the stent is reduced is by an oxidizing treatment involving exposure to superheated steam at 150° C. for 12 hours. The stent surface resulting from this treatment contains TiO2. From Auger spectroscopy, the Ni content in a surface region 10 nm deep has been found to be less than 2% by weight.
- Further electromechanical methods of polishing medical devices according to this invention are certainly possible and even likely. For instance, the sulfuric acid bath can be adequately substituted with other acid-based solutions, such as HNO3, perchloric acid, etc. Basically, the concept applied by this step is to place the medical device into the solution bath, apply a potential, and use the device as an anode in the process. Under proper conditions, electropolishing selectively removes base material, which may contain contaminants, and allows re-growth of the passive oxide on the device surface with a low Nickel content contained thereon.
- The electromechanical methods described above may further be substituted with purely chemical methods. For instance, one may use one of the following solutions:
- Acidic, e.g., 10% to 50% HNO3 (preferably 20% to 40% HNO3; more preferably 30% HNO3—water solution);
- Neutral, e.g., saline-based, such as 0.2% to 5% NaCl, preferably 0.5% to 1.5% NaCl, more preferably 0.9% NaCl—water solution;
- Basic, e.g., NaOH solutions.
- The purpose of these solutions is to provide a chemical environment to “leach” excess Nickel and other contaminants from the existing oxide surface and allow growth of a more passive (TiO2) oxide layer. Again, these surfaces possess lower Nickel content than the levels present in typical NiTi medical devices.
- In addition, the step may include anodizing. This includes exposure of the medical device to a chemical solution (acidic, neutral or basic) with an appropriately applied potential in order to grow a more stable passive oxide layer. For example, one procedure would be to immerse the NiTi medical device in a saline-based solution, and hold the potential at about 200 mV to 1000 mV, preferably 300 mV to 700 mV, more preferably 500 mV for 0.1 to 10 hours, preferably 0.2 to 2 hours, more preferably 0.5 to 1 hour.
- Of course, it is to be understood that a broad range of equivalent steps are quite possible by which to make stents according to the present invention. For instance, the rates of polishing may be adjusted depending on the desired surface finish. Also, the length of time to heat the stent with superheated steam may be adjusted depending on the size of the stent, or the number of stents heated in a batch. Furthermore, for chemical treatments, the volume of solution and duration of exposure will be adjusted according to the number of stents and the prior processing steps. What is to be realized is that the present invention is to be determined from the appended claims and their equivalents.
Claims (19)
1. A medical device which includes a component formed from an alloy which contains at least about 40% Ni by weight, the device having a 10 nm deep surface region of containing not more than about 5% Ni by weight.
2. A device as claimed in claim 1 , in which the alloy in the said surface region contains not more than about 3% Ni.
3. A device as claimed in claim 1 , in which the alloy has been subjected to polishing and oxidizing treatment on said surface region.
4. A device as claimed in claim 3 , in which the said polishing treatment comprises an electrochemical or mechanical treatment.
5. A device as claimed in claim 3 , in which the said oxidizing treatment comprises at the steps of exposure to superheated steam, a chemical treatment and an electrochemical treatment.
6. A device as claimed in claim 1 , in which the alloy is a Ni—Ti based alloy.
7. The device of claim 5 , in which the said electrochemical oxidizing treatment comprises anodizing in a acidic, neutral or basic solution.
8. A device as claimed in claim 1 , in which the device has been treated so that it exhibits superelastic properties.
9. A device as claimed in claim 1 , in which the alloy contains at least about 48% Ni by weight.
10. A device as claimed in claim 9 , in which the alloy contains at least about 50% Ni by weight.
11. A device as claimed in claim 1 , in the form of a stent.
12. A method of making a medical device comprising a component formed from an alloy which contains nickel, which includes the step of exposing the component in a surface region thereof to a treatment which causes the Ni content of the alloy in that region to be reduced compared with that in the remainder of the component.
13. The method of claim 12 wherein said device is a stent.
14. A method as claimed in claim 12 , in which the component is exposed to superheated steam.
15. A method as claimed in claim 14 , in which the component is exposed to steam for at least about 3 hours.
16. A method as claimed in claim 14 , in which the steam is heated to at least about 120° C.
17. A method as claimed in claim 13 , in which the said treatment comprises a chemical treatment, in which the device is immersed in an acidic, neutral or basic chemical solution bath.
18. A method as claimed in claim 17 , in which the said treatment comprises a chemical treatment, in which the device is immersed for at least about 0.5 hour.
19. A method as claimed in claim 12 , in which the said treatment comprises an electrochemical treatment, in which the device is included in an electrochemical system as an anode in a solution bath with current running therethrough.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/760,595 US20020092583A1 (en) | 2001-01-16 | 2001-01-16 | Medical devices, particularly stents, and methods for their manufacture |
CA002367790A CA2367790A1 (en) | 2001-01-16 | 2002-01-15 | Medical devices, particularly stents and methods for their manufacture |
AU10200/02A AU1020002A (en) | 2001-01-16 | 2002-01-16 | Medical devices, particularly stents, and methods for their manufacture |
EP02250311A EP1222901A3 (en) | 2001-01-16 | 2002-01-16 | Medical devices and methods for their manufacture |
US10/683,377 US20040117001A1 (en) | 2001-01-16 | 2003-10-10 | Medical devices, particularly stents, and methods for their manufacture |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/760,595 US20020092583A1 (en) | 2001-01-16 | 2001-01-16 | Medical devices, particularly stents, and methods for their manufacture |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/683,377 Continuation-In-Part US20040117001A1 (en) | 2001-01-16 | 2003-10-10 | Medical devices, particularly stents, and methods for their manufacture |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020092583A1 true US20020092583A1 (en) | 2002-07-18 |
Family
ID=25059578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/760,595 Abandoned US20020092583A1 (en) | 2001-01-16 | 2001-01-16 | Medical devices, particularly stents, and methods for their manufacture |
Country Status (4)
Country | Link |
---|---|
US (1) | US20020092583A1 (en) |
EP (1) | EP1222901A3 (en) |
AU (1) | AU1020002A (en) |
CA (1) | CA2367790A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050098444A1 (en) * | 2003-11-12 | 2005-05-12 | Schaeffer Darin G. | Electropolishing apparatus and method for medical implants |
US20080082158A1 (en) * | 2006-09-28 | 2008-04-03 | Cook Incorporated | Method for Deployment of a Stent Graft |
US10106908B1 (en) * | 2017-04-10 | 2018-10-23 | Ryszard Rokicki | Nitinol fatigue resistance using electropolishing, magnetoelectropolishing, anodizing and magnetoanodizing or combinations thereof under oxygen evolution regime |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7402173B2 (en) | 2000-09-18 | 2008-07-22 | Boston Scientific Scimed, Inc. | Metal stent with surface layer of noble metal oxide and method of fabrication |
US7101391B2 (en) | 2000-09-18 | 2006-09-05 | Inflow Dynamics Inc. | Primarily niobium stent |
US20040117001A1 (en) * | 2001-01-16 | 2004-06-17 | Pelton Alan R. | Medical devices, particularly stents, and methods for their manufacture |
US7727221B2 (en) | 2001-06-27 | 2010-06-01 | Cardiac Pacemakers Inc. | Method and device for electrochemical formation of therapeutic species in vivo |
US7488343B2 (en) | 2003-09-16 | 2009-02-10 | Boston Scientific Scimed, Inc. | Medical devices |
US8137397B2 (en) | 2004-02-26 | 2012-03-20 | Boston Scientific Scimed, Inc. | Medical devices |
ES2251312B1 (en) * | 2004-10-04 | 2007-07-01 | Universitat Politecnica De Catalunya | NEW TREATMENT OF OXIDATION IN ALLOYS OF NITI FOR THE DECREASE OF THE RELEASE OF IONS NI AND THE IMPROVEMENT OF BIOCOMPATIBILITY. |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
CA2659761A1 (en) | 2006-08-02 | 2008-02-07 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
CA2663271A1 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Bioerodible endoprostheses and methods of making the same |
US8808726B2 (en) | 2006-09-15 | 2014-08-19 | Boston Scientific Scimed. Inc. | Bioerodible endoprostheses and methods of making the same |
EP2959925B1 (en) | 2006-09-15 | 2018-08-29 | Boston Scientific Limited | Medical devices and methods of making the same |
CA2663303A1 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Endoprosthesis with adjustable surface features |
ES2368125T3 (en) | 2006-09-15 | 2011-11-14 | Boston Scientific Scimed, Inc. | BIOEROSIONABLE ENDOPROOTHESIS WITH BIOESTABLE INORGANIC LAYERS. |
WO2008036548A2 (en) | 2006-09-18 | 2008-03-27 | Boston Scientific Limited | Endoprostheses |
EP2277563B1 (en) | 2006-12-28 | 2014-06-25 | Boston Scientific Limited | Bioerodible endoprostheses and method of making the same |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
US8267992B2 (en) | 2009-03-02 | 2012-09-18 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
WO2014088944A1 (en) * | 2012-12-03 | 2014-06-12 | The Regents Of The University Of California | Devices, systems and methods for coating surfaces |
CN113042975B (en) * | 2021-03-08 | 2023-07-28 | 沛县盛玛特新材料研究院有限公司 | Treatment method for improving surface quality of medical metal stent and medical metal stent |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3617360A (en) * | 1968-11-29 | 1971-11-02 | Gen Electric | High temperature metallic diffusion coating and method |
US4148699A (en) * | 1976-07-20 | 1979-04-10 | Heritage Silversmiths Limited | Electropolishing of stainless steel |
US4612061A (en) * | 1984-03-15 | 1986-09-16 | Kabushiki Kaisha Toshiba | Method of manufacturing picture tube shadow mask |
US4774150A (en) * | 1986-03-07 | 1988-09-27 | Kabushiki Kaisha Toshiba | Thermal barrier coating |
US4799127A (en) * | 1986-07-29 | 1989-01-17 | Tdk Corporation | Semiconductive ceramic composition and semiconductor ceramic capacitor |
US5277788A (en) * | 1990-10-01 | 1994-01-11 | Aluminum Company Of America | Twice-anodized aluminum article having an organo-phosphorus monolayer and process for making the article |
US5630887A (en) * | 1995-02-13 | 1997-05-20 | Novacor Chemicals Ltd. | Treatment of furnace tubes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1076763C (en) * | 1998-09-09 | 2001-12-26 | 北京航空航天大学 | In-situ preparing of insulating film on surface of marmem |
-
2001
- 2001-01-16 US US09/760,595 patent/US20020092583A1/en not_active Abandoned
-
2002
- 2002-01-15 CA CA002367790A patent/CA2367790A1/en not_active Abandoned
- 2002-01-16 AU AU10200/02A patent/AU1020002A/en not_active Abandoned
- 2002-01-16 EP EP02250311A patent/EP1222901A3/en not_active Withdrawn
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3617360A (en) * | 1968-11-29 | 1971-11-02 | Gen Electric | High temperature metallic diffusion coating and method |
US4148699A (en) * | 1976-07-20 | 1979-04-10 | Heritage Silversmiths Limited | Electropolishing of stainless steel |
US4612061A (en) * | 1984-03-15 | 1986-09-16 | Kabushiki Kaisha Toshiba | Method of manufacturing picture tube shadow mask |
US4774150A (en) * | 1986-03-07 | 1988-09-27 | Kabushiki Kaisha Toshiba | Thermal barrier coating |
US4799127A (en) * | 1986-07-29 | 1989-01-17 | Tdk Corporation | Semiconductive ceramic composition and semiconductor ceramic capacitor |
US4854936A (en) * | 1986-07-29 | 1989-08-08 | Tdk Corporation | Semiconductive ceramic composition and semiconductive ceramic capacitor |
US5277788A (en) * | 1990-10-01 | 1994-01-11 | Aluminum Company Of America | Twice-anodized aluminum article having an organo-phosphorus monolayer and process for making the article |
US5630887A (en) * | 1995-02-13 | 1997-05-20 | Novacor Chemicals Ltd. | Treatment of furnace tubes |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050098444A1 (en) * | 2003-11-12 | 2005-05-12 | Schaeffer Darin G. | Electropolishing apparatus and method for medical implants |
US7252746B2 (en) | 2003-11-12 | 2007-08-07 | Cook Incorporated | Electropolishing apparatus and method for medical implants |
US20070209929A1 (en) * | 2003-11-12 | 2007-09-13 | Cook Incorporated | Electropolishing apparatus and method for medical implants |
US20100181206A1 (en) * | 2003-11-12 | 2010-07-22 | Cook Incorporated | Method of electropolishing medical implants |
US7799201B2 (en) | 2003-11-12 | 2010-09-21 | Cook Incorporated | Method of electropolishing medical implants |
US7799183B2 (en) | 2003-11-12 | 2010-09-21 | Cook Incorporated | Electropolishing apparatus and method for medical implants |
US20080082158A1 (en) * | 2006-09-28 | 2008-04-03 | Cook Incorporated | Method for Deployment of a Stent Graft |
US20080082159A1 (en) * | 2006-09-28 | 2008-04-03 | Cook Incorporated | Stent for Endovascular Procedures |
US20080082154A1 (en) * | 2006-09-28 | 2008-04-03 | Cook Incorporated | Stent Graft Delivery System for Accurate Deployment |
US10106908B1 (en) * | 2017-04-10 | 2018-10-23 | Ryszard Rokicki | Nitinol fatigue resistance using electropolishing, magnetoelectropolishing, anodizing and magnetoanodizing or combinations thereof under oxygen evolution regime |
Also Published As
Publication number | Publication date |
---|---|
EP1222901A3 (en) | 2002-07-24 |
AU1020002A (en) | 2002-07-18 |
CA2367790A1 (en) | 2002-07-16 |
EP1222901A2 (en) | 2002-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20020092583A1 (en) | Medical devices, particularly stents, and methods for their manufacture | |
US20040117001A1 (en) | Medical devices, particularly stents, and methods for their manufacture | |
US11015253B2 (en) | Surface treatment process for implants made of titanium alloy | |
US6679980B1 (en) | Apparatus for electropolishing a stent | |
Zhao et al. | Electrochemical polishing of 316L stainless steel slotted tube coronary stents | |
CA2499453C (en) | Balloon expandable superelastic stent | |
Raval et al. | Development and assessment of 316LVM cardiovascular stents | |
EP1355685B1 (en) | Radiopaque nitinol alloys for medical devices | |
US20090010796A1 (en) | Long fatigue life nitinol | |
JP2007516772A (en) | Metal alloy cleaning and polishing method and product cleaned or polished thereby | |
WO2005104993A2 (en) | Amorphous oxide surface film for metallic implantable devices and method for production thereof | |
EP2885074B1 (en) | Surface oxide removal methods | |
Biscarini et al. | Enhanced nitinol properties for biomedical applications | |
JP2007006941A (en) | Medical material and its manufacturing method | |
Mani et al. | Surface finishing of N itinol for implantable medical devices: A review | |
US20130092555A1 (en) | Removal of an island from a laser cut article | |
US20130004362A1 (en) | Process for production of medical instrument, and medical instrument | |
JP5355972B2 (en) | Stent manufacturing method | |
Sojitra et al. | Surface enhancement and characterization of L-605 cobalt alloy cardiovascular stent by novel electrochemical treatment | |
Korolyov et al. | Electrolytic plasma polishing of NiTi alloy | |
WO2011118401A1 (en) | Process for production of medical instrument, and medical instrument | |
CN113042975B (en) | Treatment method for improving surface quality of medical metal stent and medical metal stent | |
Kathuria | Biocompatible metallic stent for medical therapy | |
Sholihin et al. | Effect of annealing on surface oxidation of Ti-50.8 at% Ni shape memory alloy | |
Rondelli et al. | Corrosion Behaviour of Nitinol Vascular Stents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NITINOL DEVELOPMENT CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PELTON, ALAN R.;TREPANIER, CHRISTINE;REEL/FRAME:011826/0486 Effective date: 20010511 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |